Renal Diseases Market Reports Empesis on Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease

The Frontier Pharma: Renal Diseases High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease assesses first-in-class innovation in the renal diseases pipeline, highlighting key trends and emerging treatment classes.

Pune, India - March 14, 2018 /MarketersMedia/ —

The renal diseases therapy area encompasses a range of diseases of the kidney, such as chronic kidney disease (CKD), acute kidney injury, diabetic nephropathy and focal segmental glomerulosclerosis. Renal diseases are becoming increasingly common due to the increased prevalence of hypertension and diabetes, two major causes of CKD. For most forms of renal diseases, early detection and management may slow down or prevent progression to renal failure and associated complications. However, many renal diseases are typically asymptomatic until they have progressed to end-stage renal disease (ESRD), which requires renal replacement therapies such as hemodialysis and renal transplantation, and is associated with substantial morbidity and mortality.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-renal-diseases-high-degree-of-innovation-and-diversity-with-products-targeting-immune-and-hormone-signaling-dominating-the-pipeline-for-chronic-kidney-disease

The first-in-class programs identified show considerable diversity, and the relatively high degree of innovation in the renal diseases therapy area makes for a promising development pipeline. It is clear that recent activity in this area has increased, partly owing to the growing recognition of the unmet medical need. Further investment in innovation would benefit the therapy area greatly, and likely prove a worthwhile investment, particularly for highly prevalent diseases such as CKD and diabetic nephropathy, for which there are a lack of effective pharmacotherapeutic options.

Get this report at: https://www.themarketreports.com/report/buy-now/935551

Scope
• With 365 products in active development, the pipeline is modestly sized. Does current pipeline innovation hold the potential to affect the future renal diseases market?
• There are 100 first-in-class products in the renal diseases pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
• The majority of first-in-class products were in development for indications involving inflammation. Which first-in-class targets are most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
• A significant number of first-in-class products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935551

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/renal-diseases-market-reports-empesis-on-targeting-immune-and-hormone-signaling-dominating-the-pipeline-for-chronic-kidney-disease/314328

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-renal-diseases-high-degree-of-innovation-and-diversity-with-products-targeting-immune-and-hormone-signaling-dominating-the-pipeline-for-chronic-kidney-disease%20%20

Source: MarketersMedia

Release ID: 314328

More Press Releases

Global stocks tumble after new Trump tariff threat

Jun 19, 2018

BEIJING — Global stock markets fell Tuesday after U.S. President Donald Trump escalated a dispute with China over technology policy by threatening a tariff hike on an additional $200 billion of Chinese goods. KEEPING SCORE: Germany's DAX was down a sharp 1.3 percent to 12,673 and France's CAC 40 fell 1.1 percent to 5,394. London's FTSE 100 lost 0.4 percent to 7,598. Wall Street looked poised for heavy losses, with the future for the Dow Jones industrial average off 1.3 percent and that for the Standard & Poor's 500 index down 1.1 percent. ASIA'S DAY: The losses were even heavier...

Asian stocks tumble after new Trump tariff threat

Jun 19, 2018

BEIJING — Asian stocks tumbled Tuesday after U.S. President Donald Trump escalated a dispute with Beijing over technology policy by threatening a tariff hike on additional Chinese goods. KEEPING SCORE: The Shanghai Composite Index fell 2.3 percent to 2,953.54 points and Hong Kong's Hang Seng lost 2 percent to 29,685.28. Tokyo's Nikkei 225 retreated 0.9 percent to 22,482.89 and Seoul's Kospi lost 0.8 percent to 2,356.57. Markets in Taiwan, New Zealand and Southeast Asia also declined. Sydney's S&P-ASX 200 gained 0.3 percent to 6,123.00. TRADE TENSIONS: Trump directed the U.S. Trade Representative to prepare new tariffs on $200 billion in...

Markets Right Now: Stocks look to recover from early skid

Jun 19, 2018

NEW YORK — The latest on developments in financial markets (all times local): 4:00 p.m. Stocks are closing mixed Monday after recovering from early losses. Energy stocks helped the comeback. Chevron gained 1.5 percent, getting a boost from a 1.2 percent rise in the price of U.S. crude oil. Some big technology shares also posted gains. Alphabet, the parent company of Google, rose 2.1 percent. Smaller and more U.S.-focused companies climbed higher. The Russell 2000 index added 0.5 percent to a record 1,692.45. Health care companies weighed on the market, however. Pharmaceutical and biotechnology companies fell. Household goods companies took...

World stocks slide over trade tensions, German politics

Jun 19, 2018

SINGAPORE — Global stocks dropped Monday on concerns over trade as the U.S. and China scheduled the start of tariffs on each other's goods, and a row over migrants threatened the German government. Markets in China and Hong Kong were closed for a holiday. KEEPING SCORE: Germany's DAX lost 1.3 percent to 12,839 and France's CAC 40 shed 1.2 percent to 5,433. Britain's FTSE 100 dipped 0.4 percent to 7,605. Wall Street was poised to open lower. Dow futures dropped 0.7 percent and the S&P 500 futures were down 0.6 percent. U.S.-CHINA TARIFFS: Tariffs mooted by the world's two biggest...

US stocks and bond yields dip amid trade worries

Jun 19, 2018

NEW YORK — U.S. stocks closed out a whirlwind week with a modest loss Friday as markets gauged how much to fret about the Trump administration's decision to step up the trade dispute between the world's two biggest economies. The White House announced tariffs on $50 billion of imports from China, and China's almost-immediate response was a promise to retaliate with its own of the same scale. Stocks sank from the start of trading, and the S&P 500 was down 0.7 percent at one point before paring its loss as the day progressed. At the close, the S&P 500 was...

Subscribe to our newsletter!

Your Name

Your Email Address